Get the Stockscreener App
1.70
65.24%
-3.19
After Hours:
1.68
-0.02
-1.18%
Outlook Therapeutics Inc stock is traded at $1.70, with a volume of 62.14M.
It is down -65.24% in the last 24 hours and down -68.75% over the past month.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
See More
Previous Close:
$4.89
Open:
$0.981
24h Volume:
62.14M
Relative Volume:
51.30
Market Cap:
$115.68M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-6.80
EPS:
-0.25
Net Cash Flow:
$-47.10M
1W Performance:
-67.80%
1M Performance:
-68.75%
6M Performance:
-78.48%
1Y Performance:
-82.00%
1-Day Range:
$0.87
$2.21
1-Week Range:
$0.87
$5.29
52-Week Range:
$0.87
$12.85
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.70 | 115.68M | 0 | -51.50M | -47.10M | -0.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Outlook Holds Out Hope For Wet AMD Approval Despite Phase III Topline Miss - Scrip
Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial - Yahoo Finance
Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial - Clinical Trials Arena
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? - Yahoo Finance
Outlook Therapeutics reports NORSE EIGHT trial results; shares slump By Investing.com - Investing.com South Africa
Outlook Therapeutics reports NORSE EIGHT trial results; shares slump - Investing.com
Outlook plunges as lead asset fails in wet AMD study - MSN
Outlook Therapeutics Trial of Eye Disease Treatment Misses Key Endpoint - MarketWatch
Great Point Partners LLC Sells 408,482 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
Outlook stock plunges after study setback (OTLK:NASDAQ) - Seeking Alpha
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial - Marketscreener.com
Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $48.20 - Defense World
Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK), - Yahoo Finance
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
OTLK (Outlook Therapeutics) EV-to-Revenue : (As of Nov. 23, 2024) - GuruFocus.com
Metrics That Matter About Iterum Therapeutics Plc (NASDAQ: ITRM) - Stocks Register
Thinking Of Investing In Outlook Therapeutics Inc (NASDAQ: OTLK) Stock? Here’s What You Need To Know - Stocks Register
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - PR Newswire
(OTLK) Trading Signals - Stock Traders Daily
Great Point Partners LLC Bolsters Position in Outlook Therapeuti - GuruFocus.com
Learn to Evaluate (OTLK) using the Charts - Stock Traders Daily
Velan Capital Investment Management LP Increases Stake in Outloo - GuruFocus.com
Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Aterian Investment Partners acquires Outlook Group to support growth - Packaging Gateway
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewswire
Outlook Therapeutics CEO to Present at Guggenheim Healthcare Conference After EU Win | OTLK Stock News - StockTitan
Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Simply Wall St
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
The United States Gastroesophageal Reflux Disease Therapeutics Market Size & Outlook, 2030 - Grand View Research
Outlook Therapeutics' (OTLK) Buy Rating Reiterated at BTIG Research - MarketBeat
Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment - Marketscreener.com
How the (OTLK) price action is used to our Advantage - Stock Traders Daily
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment - GlobeNewswire
Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Severe Acute Respiratory Syndrome (SARS) Therapeutics Market 2023 Outlook By Product, Trends and Forecast To (2024-2034) – IndiaPolitics.com - IndiaPolitics.com
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ForexTV.com
ROSEN, A LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important - EIN News
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Outlook Therapeutics Awaits Wet AMD Trial Results Of ONS-5010 - RTTNews
OTLK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionOTLK - AsiaOne
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(OTLK) On The My Stocks Page - Stock Traders Daily
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts - Benzinga
Outlook Therapeutics CFO buys $28.4k in company stock - Investing.com India
Insider Buying: CFO Lawrence Kenyon Acquires Shares of Outlook T - GuruFocus.com
Outlook Therapeutics CFO buys $28.4k in company stock By Investing.com - Investing.com Australia
Neumora Therapeutics' SWOT analysis: navacaprant's potential lifts stock outlook - Investing.com
Great Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
(OTLK) Investment Analysis - Stock Traders Daily
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Outlook Therapeutics Inc Stock (OTLK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Haddadin Yezan Munther | Director |
Mar 28 '24 |
Buy |
11.82 |
1,882 |
22,242 |
5,049 |
| Evanson Jeff | CHIEF COMMERCIAL OFFICER |
Mar 07 '24 |
Buy |
0.42 |
62,484 |
26,243 |
808,459 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):